This Site makes heavy use of JavaScript

Either you have JavaScript disabled or your browser does not support JavaScript.

To work properly, this page requires JavaScript to be enabled. If you can enable it in your browser's preferences, you may have a better experience.

Reversing Pradaxa® (dabigatran etexilate) | PRADAXA Reversal Skip to main content

NOAC=novel oral anticoagulant; OAC=oral anticoagulant.

  • References:
  • 1. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.
  • 2. American College of Cardiology. Update on reversal agents for novel oral anticoagulants. http://www.acc.org/latest-in-cardiology/articles/2015/12/11/08/20/update-on-reversal-agents-for-novel-oral-anticoagulants. Accessed October 19, 2016.
  • 3. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. [published correction appears in Circulation. 2014;130:e199-e267.] Circulation. 2014;129:1-123.
  • 4. Pradaxa [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.